AKT1 and ovarian carcinoma: Yang et al. found that phosphatidylinositide 3-kinase/protein kinase B (PI3K/AKT) has a significant effect on cisplatin resistance in human epithelial ovarian cancer, and the inhibition of the PI3K/AKT pathway can significantly increase the sensitivity of tumour cells to cisplatin [104].